CN Patent

CN111297863B — menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用

Assigned to West China Hospital of Sichuan University · Expires 2021-06-25 · 5y expired

What this patent protects

本发明公开了menin‑MLL抑制剂在制备治疗子宫内膜癌的药物中的应用，属于抗肿瘤药物领域。menin‑MLL抑制剂作为一种常见的治疗白血病的药物，从未被报道过可以用于治疗子宫内膜癌。本发明证实了menin‑MLL抑制剂对子宫内膜癌具有显著的抑制效果，本发明关于将menin‑MLL抑制剂用于制备治疗子宫内膜癌的药物中的应用具有良好的市场前景。

USPTO Abstract

本发明公开了menin‑MLL抑制剂在制备治疗子宫内膜癌的药物中的应用，属于抗肿瘤药物领域。menin‑MLL抑制剂作为一种常见的治疗白血病的药物，从未被报道过可以用于治疗子宫内膜癌。本发明证实了menin‑MLL抑制剂对子宫内膜癌具有显著的抑制效果，本发明关于将menin‑MLL抑制剂用于制备治疗子宫内膜癌的药物中的应用具有良好的市场前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN111297863B
Jurisdiction
CN
Classification
—
Expires
2021-06-25
Drug substance claim
No
Drug product claim
No
Assignee
West China Hospital of Sichuan University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.